Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-cash Items: 2012-2024

Historic Non-cash Items for Anika Therapeutics (ANIK) over the last 3 years, with Sep 2024 value amounting to $248,000.

  • Anika Therapeutics' Non-cash Items rose 2380.00% to $248,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $248,000, marking a year-over-year increase of 2380.00%. This contributed to the annual value of $127,000 for FY2023, which is 87.90% down from last year.
  • As of Q3 2024, Anika Therapeutics' Non-cash Items stood at $248,000, which was down 17.33% from $300,000 recorded in Q2 2024.
  • Over the past 5 years, Anika Therapeutics' Non-cash Items peaked at $4.7 million during Q3 2021, and registered a low of $9,000 during Q1 2022.
  • Over the past 3 years, Anika Therapeutics' median Non-cash Items value was $188,000 (recorded in 2023), while the average stood at $270,818.
  • As far as peak fluctuations go, Anika Therapeutics' Non-cash Items crashed by 98.32% in 2022, and later soared by 6,922.22% in 2023.
  • Over the past 5 years, Anika Therapeutics' Non-cash Items (Quarterly) stood at $2.8 million in 2020, then slumped by 65.18% to $975,000 in 2021, then increased by 7.69% to $1.1 million in 2022, then slumped by 87.90% to $127,000 in 2023, then skyrocketed by 2,380.00% to $248,000 in 2024.
  • Its last three reported values are $248,000 in Q3 2024, $300,000 for Q2 2024, and $316,000 during Q1 2024.